Skip to main content
    E

    Envista Holdings Corp (NVST)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $24.05
    -0.44 (-1.80%)

    Market Cap: $3.93B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Envista Holdings Corp (NVST) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Envista Holdings (NVST) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Envista Holdings reported EPS of $0.40, above the $0.35 estimate. It beat the EPS estimate in each of the last 9 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    76%(22/29)
    Avg Surprise
    +22.57%
    Streak
    9 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.41
    Range$0.38 - $0.44
    17 analysts
    Revenue Consensus
    $761.49M
    Range$723.53M - $806.51M
    15 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.39
    Range$0.35 - $0.42
    10 analysts
    EPS Estimate DriftChange to current
    90d ago$0.39-0.2%
    60d ago$0.39-0.1%
    30d ago$0.39+0.2%
    7d ago$0.39+0.8%
    Current$0.39
    Revenue Consensus
    $716.87M
    Range$706.70M - $726.70M
    6 analysts

    Next Report

    NVST has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.9% above the $0.38 reported for the quarter ended Dec 31, 2025.

    NVST Earnings Call

    The latest NVST earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, NVST beat 22, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $691.50M, up 3.2% from $669.90M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.40$0.35$0.34 - $0.38+14.29%Beat+25.0%150 up, 6 downNov 4, 2026$691.50M
    Jun 30, 2026$0.41$0.33$0.29 - $0.36+24.24%Beat+57.7%161 up, 0 downAug 5, 2026$730.50M
    Mar 31, 2026$0.36$0.31$0.29 - $0.33+16.13%Beat+50.0%15N/AMay 6, 2026$705.50M
    Dec 31, 2025$0.38$0.32$0.31 - $0.34+18.75%Beat+58.3%150 up, 1 downFeb 5, 2026$750.60M
    Sep 30, 2025$0.32$0.28$0.24 - $0.32+14.29%Beat+166.7%141 up, 0 downOct 29, 2025$669.90M
    Jun 30, 2025$0.26$0.23$0.21 - $0.24+13.04%Beat+136.4%131 up, 0 downJul 31, 2025$682.10M
    Mar 31, 2025$0.24$0.20$0.19 - $0.24+20.00%Beat-7.7%132 up, 1 downMay 1, 2025$616.90M
    Dec 31, 2024$0.24$0.22$0.16 - $0.27+9.09%Beat-17.2%142 up, 6 downFeb 5, 2025$652.90M
    Sep 30, 2024$0.12$0.09$0.05 - $0.13+33.33%Beat-72.1%120 up, 1 downOct 30, 2024$601.00M
    Jun 30, 2024$0.11$0.28$0.15 - $0.35-60.71%Miss-74.4%120 up, 3 downAug 7, 2024$633.10M
    Mar 31, 2024$0.26$0.32$0.26 - $0.35-18.75%Miss-31.6%131 up, 1 downMay 1, 2024$623.60M
    Dec 31, 2023$0.29$0.34$0.30 - $0.39-14.71%Miss-44.2%110 up, 1 downFeb 7, 2024$645.60M
    Sep 30, 2023$0.43$0.46$0.43 - $0.49-6.52%Miss-8.5%100 up, 0 downNov 1, 2023$631.30M
    Jun 30, 2023$0.43$0.41$0.39 - $0.42+4.88%Beat-10.4%100 up, 3 downAug 2, 2023$662.40M
    Mar 31, 2023$0.38$0.41$0.38 - $0.44-7.32%Miss-19.1%100 up, 0 downMay 3, 2023$627.20M
    Dec 31, 2022$0.52$0.49$0.46 - $0.52+6.12%Beat+13.0%100 up, 0 downFeb 8, 2023$660.80M
    Sep 30, 2022$0.47$0.47$0.45 - $0.500.00%In line+4.4%90 up, 1 downNov 3, 2022$631.10M
    Jun 30, 2022$0.48$0.46$0.43 - $0.51+4.35%Beat-9.4%91 up, 1 downAug 3, 2022$645.80M
    Mar 31, 2022$0.47$0.43$0.40 - $0.46+9.30%Beat-13.0%90 up, 0 downMay 4, 2022$631.40M
    Dec 31, 2021$0.46$0.42$0.39 - $0.47+9.52%Beat-17.9%10N/AFeb 9, 2022$651.80M
    Sep 30, 2021$0.45$0.41$0.36 - $0.45+9.76%Beat-6.2%10N/ANov 3, 2021$607.30M
    Jun 30, 2021$0.53$0.45$0.41 - $0.52+17.78%BeatN/A11N/AAug 3, 2021$637.20M
    Mar 31, 2021$0.54$0.31$0.25 - $0.37+74.19%Beat+1700.0%11N/AMay 5, 2021$612.60M
    Dec 31, 2020$0.56$0.42$0.36 - $0.47+33.33%Beat+7.7%12N/AFeb 10, 2021$472.70M
    Sep 30, 2020$0.48$0.09-$0.02 - $0.21+433.33%Beat+2.1%11N/AOct 29, 2020$547.20M
    Jun 30, 2020-$0.10-$0.23-$0.42 - -$0.13+56.52%Beat-120.8%11N/AJul 30, 2020$362.00M
    Mar 31, 2020$0.03$0.12-$0.14 - $0.23-75.00%MissN/A10N/AMay 12, 2020$547.20M
    Dec 31, 2019$0.52$0.49$0.48 - $0.51+6.12%BeatN/A10N/AJan 30, 2020$720.50M
    Sep 30, 2019$0.47$0.43$0.40 - $0.45+9.30%BeatN/A10N/AOct 24, 2019$659.30M
    Jun 30, 2019$0.48N/AN/AN/AN/AN/AN/AN/AJul 22, 2019$712.10M
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.20, up 64.4% from the year before. It was $1.47 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.20+64.4%
    Dec 31, 2024$0.73-52.3%
    Dec 31, 2023$1.53-21.1%
    Dec 31, 2022$1.94N/A
    Dec 31, 2021$1.98+104.1%
    Dec 31, 2020$0.97-34.0%
    Dec 31, 2019$1.47N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,04212
    2026Q2Jun 30, 20268,77815
    2026Q1Mar 31, 20266,94813
    2025Q4Dec 31, 20258,48810
    2025Q3Sep 30, 20257,76316
    2025Q2Jun 30, 20258,13814
    2025Q1Mar 31, 20257,99313
    2024Q4Dec 31, 20248,41314

    2026Q3 Earnings Call

    Opening remarks

    Jim Gustafson Vice President of Investor Relations Good afternoon. Thank you for joining Envista's Third Quarter 2026 Earnings Call. We appreciate your interest in our company. With me today are Paul Keel, our President and Chief Executive Officer; and Eric Hammes, our Chief Financial Officer. Our earnings release, the slide presentation supplementing today's call, and reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are available in the Investors section of our website, www.envistaco.com. The audio portion of this call will be archived in the Investors section of our website later today under the heading Events and Presentations. During the presentation, we will describe some of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted our results. Unless otherwise noted, references in these remarks to company-specific financial metrics relate to the third quarter of 2026, and references to period-to-period increases and decreases in financial metrics are year-over-year. During the call, we may describe certain products and solutions that have applications submitted and pending certain regulatory approvals or are available only in certain markets. We will also make forward-looking statements within the meaning of the federal securities laws, including statements regarding events and developments that we believe or anticipate may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. With that, I'll turn the call over to Paul.

    Paul Keel President and Chief Executive Officer Thanks, Jim, and hello to everyone joining us today. I'll start with an overview of the quarter, including strategic and operational progress made in support of our longer-term value creation plan. Eric will then take us through the numbers in more detail. I will wrap things up with a few closing thoughts before we take your questions. As shown on Slide 4, we delivered core sales growth of 2.7% in Q3 with adjusted EBITDA growth of 9% and adjusted EPS growth of 25%. On a global scale, we did not observe any material shifts in the dental market in Q3 relative to the first half of the year. From a sector perspective, insurance-covered categories like prevention, diagnostics, and restoration displayed their characteristic resilience, while more elective categories like ortho and implants continued to run below their higher historical trends. From a geographic perspective, developing markets, excluding China, continued to grow most quickly, followed by Europe.

    Frequently Asked Questions About NVST

    When is Envista Holdings's next earnings date?

    Envista Holdings's next earnings report is expected for Feb 3, 2027.

    Did NVST beat earnings estimates last quarter?

    Yes. Envista Holdings reported EPS of $0.40 for the quarter ended Sep 30, 2026, above the $0.35 estimate, a 14.29% surprise.

    What EPS do analysts expect from NVST next quarter?

    The consensus EPS estimate for Envista Holdings for the quarter ending Dec 31, 2026 is $0.41 from 17 analysts, with estimates from $0.38 to $0.44.

    How often does NVST beat earnings estimates?

    Envista Holdings beat the EPS estimate in each of the last 9 quarters, with an average surprise of +18.13%.